Adenoviral-mediated over-expression of Brn2 in the rat paraventricular nucleus: No effect on vasopressin or corticotrophin releasing factor RNA levels

Molecular and Cellular Endocrinology

Volumn 200, Issue 1-2, 2003, Pages 165-175

  Wong, Liang Fong ^a,b   Murphy, David ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b OXFORD BIOMEDICA UK LTD   (United Kingdom)

Author keywords

Adenoviral vector; Brn2; Corticotrophin releasing factor; Overexpression; Paraventricular nucleus; Vasopressin

Indexed keywords

ADENOVIRUS VECTOR; CIS ACTING ELEMENT; CORTICOTROPIN RELEASING FACTOR; HETEROGENEOUS NUCLEAR RNA; MESSENGER RNA; RNA; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR BRN2; UNCLASSIFIED DRUG; VASOPRESSIN; VASOPRESSIN RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL LINE; CONTROLLED STUDY; DNA FLANKING REGION; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HYPOTHALAMUS; HYPOTHESIS; IN VIVO STUDY; KNOCKOUT MOUSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN LOCALIZATION; RAT; REPORTER GENE; THALAMUS MIDLINE NUCLEUS; TRANSACTIVATION; UPREGULATION;

ADENOVIRIDAE; ADULT; ANIMALS; CELL LINE; CELL LINE, TUMOR; CORTICOTROPIN-RELEASING HORMONE; GENE EXPRESSION REGULATION; GENETIC VECTORS; HOMEODOMAIN PROTEINS; HUMANS; MICE; MODELS, GENETIC; PARAVENTRICULAR HYPOTHALAMIC NUCLEUS; POU DOMAIN FACTORS; PROMOTER REGIONS (GENETICS); RATS; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER; TRANSCRIPTION FACTORS; VASOPRESSINS;

EID: 0037469655     PISSN: 03037207     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0303-7207(02)00355-6     Document Type: Article

References (49)

1. Alvarez-Bolado G., Rosenfeld M.G., Swanson L.W. Model of forebrain regionalization based on spatiotemporal patterns of POU-III homeobox gene expression, birthdates, and morphological features. J. Comp. Neurol. 355:1995;237-295.
2. Ang H.-L., Carter D.A., Murphy D. Neuron-specific and physiological regulation of bovine vasopressin transgenes in mice. EMBO J. 12:1993;2397-2409.
3. Antoni F.A. Vasopressinergic control of pituitary adrenocorticotropin secretion comes of age. Front Neuroendocrinol. 14:1993;76-122.
4. Bourque C.W., Oliet S.H., Richard D. Osmoreceptors, osmoreception, and osmoregulation. Front Neuroendocrinol. 15:1994;231-274.
5. Bradford A.P., Wasylyk C., Wasylyk B., Gutierrez-Hartmann A. Interaction of Ets-1 and the POU-homeodomain protein GHF-1/Pit-1 reconstitutes pituitary-specific gene expression. Mol. Cell. Biol. 17:1997;1065-1074.
6. Gainer H., Young W.S. Transgenic models for studies of oxytocin and vasopressin. Castro M. Transgenic Models In Endocrinology. 2001;25-46 Kluwer, London.
7. Gillies G.E., Linton E.A., Lowry P.J. Corticotropin releasing activity of the new CRF is potentiated several times by vasopressin. Nature. 299:1982;355-357.
8. Gossen M., Bujard H. Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc. Natl. Acad. Sci. USA. 89:1992;5547-5551.
9. Gossen M., Freundlieb S., Bender G., Muller G., Hillen W., Bujard H. Transcriptional activation by tetracyclines in mammalian cells. Science. 268:1995;1766-1769.
10. Graham F.L., Prevec L. Methods for construction of adenovirus vectors. Mol. Biotechnol. 3:1995;207-220.
11. Graham F.L., Smiley J., Russell W.C., Nairn R. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J. Gen. Virol. 36:1977;59-74.
12. Harding T.C., Geddes B.J., Noel J.D., Murphy D., Uney J.B. Tetracycline-regulated transgene expression in hippocampal neurones following transfection with adenoviral vectors. J. Neurochem. 69:1997;2620-2623.
13. Harding T.C., Geddes B.J., Murphy D., Knight D., Uney J.B. Switching transgene expression in the brain using an adenoviral tetracycline-regulatable system. Nat. Biotechnol. 16:1998;553-555.
14. He X., Treacy M.N., Simmons D.M., Ingraham H.A., Swanson L.W., Rosenfeld M.G. Expression of a large family of POU-domain regulatory genes in mammalian brain development. Nature. 340:1989;35-41.
15. Herman J.P., Schafer M.K., Watson S.J., Sherman T.G. In situ hybridization analysis of arginine vasopressin gene transcription using intron-specific probes. Mol Endocrinol. 5:1991;1447-1456.
16. Herskowitz I. Functional inactivation of genes by dominant negative mutations. Nature. 329:1987;219-222.
17. Honda K., Negoro H., Dyball R.E., Higuchi T., Takano S. The osmoreceptor complex in the rat: evidence for interactions between the supraoptic and other diencephalic nuclei. J. Physiol. (London). 431:1990;225-241.
18. Jang S.K., Krausslich H.-G., Nicklin M.J.H., Duke G.M., Palmenberg A.C., Wimmer E. A segment of the 5′ nontranslated region of encephalomyocarditis virus RNA directs internal entry of ribosomes during in vitro translation. J. Virol. 62:1988;2636-2643.
19. Jeong S.W., Castel M., Zhang B.J., Fields R.L., Paras P., Arnheiter H., Chin H., Gainer H. Cell-specific expression and subcellular localization of neurophysin-CAT-fusion proteins expressed from oxytocin and vasopressin gene promoter-driven constructs in transgenic mice. Exp. Neurol. 171:2001;255-271.
20. Kalsbeek A., Van Der Vliet J., Buijs R.M. Decrease of endogenous vasopressin release necessary for expression of the circadian rise in plasma corticosterone: a reverse microdialysis study. J. Neuroendocrinol. 8:1996;299-307.
21. Kalsbeek A., van Heerikhuiz J.J., Wortel J., Buijs R.M. A diurnal rhythm of stimulatory input to the hypothalamo-pituitary-adrenal system as revealed by timed intrahypothalamic administration of the vasopressin V1 antagonist. J. Neurosci. 16:1996;5555-5565.
22. Le Moine C., Young W.S. RHS2, a POU domain-containing gene, and its expression in developing and adult rat. Proc. Natl. Acad. Sci. USA. 89:1992;3285-3289.
23. Li P., He X., Gerrero M.R., Mok M., Aggarwal A., Rosenfeld M.G. Spacing and orientation of bipartite DNA-binding motifs as potential functional determinants for POU domain factors. Genes Dev. 7:1993;2483-2496.
24. Miklos G.L.G., Rubin G.M. The role of the genome project in determining gene function: insights from model organisms. Cell. 86:1996;521-529.
25. Moore R.Y. Organization and function of a central nervous system circadian oscillator: the suprachiasmatic hypothalamic nucleus. Fed. Proc. 42:1983;2783-2789.
26. Mossman T. Rapid colorimetric assay for cellular growth and cytotoxicity assays. J. Immunol. Methods. 65:1983;55-63.
27. Nakai S., Kawano H., Yudate T., Nishi M., Kuno J., Nagata A., Jishage K., Hamada H., Fujii H., Kawamura K., Shiba K., Noda T. The POU domain transcription factor Brn2 is required for the determination of specific neuronal lineages in the hypothalamus of the mouse. Genes Dev. 9:1995;3109-3121.
28. Pardy K. Reporter enzymes for the study of promoter activity. Mol. Biotechnol. 2:1994;23-28.
29. Paton J.F.R., Deuchars J., Ahmad Z., Wong L.-F., Murphy D., Kasparov S. Adeno viral vector demonstrates that angiotensin II induced depression of the cardiac baroreflex is mediated by endothelial nitric oxide synthase in the nucleus tractus solitarii. J. Physiol. 531:2001;445-458.
30. Paxinos G., Watson C. The Rat Brain in Stereotaxic Coordinates. 1982;Academic Press, New York.
31. Pelletier J., Sonenberg N. Internal initiation of translation of eukaryotic mRNA directed by a sequence derived from poliovirus RNA. Nature. 334:1988;320-325.
32. Ramkumar T., Adler S. A requirement for the POU transcription factor, Brn2, in corticotropin-releasing hormone expression in a neuronal cell line. Mol. Endocrinol. 13:1999;1237-1248.
33. Reeves W.B., Andreoli T.E. The posterior pituitary and water metabolism. Wilson J.D., Foster D.W. William's Textbook of Endocrinology. 1992;311-356 Saunders, Philadelphia.
34. Scharrer E., Scharrer B. Hormones produced in neurosecretory cells. Recent Progr. Hormone Res. 10:1954;183-240.
35. Schonemann M.D., Ryan A.K., McEvilly R.J., O'Connell S.M., Arias C.A., Kalla K.A., Li P., Sawchenko P.E., Rosenfeld M.G. Development and survival of the endocrine hypothalamus and posterior pituitary gland requires the neuronal POU domain factor Brn2. Genes Dev. 9:1995;3122-3135.
36. Schreiber E., Himmelmann A., Malipiero U., Tobler A., Stahel R., Fontana A. Human small cell lung cancer expresses the octomer DNA-binding and nervous system-specific transcription factor N-Oct 3 (Brain-2). Cancer Res. 52:1992;6121-6124.
37. Schrier R.W. Vasopressin. 1985;Raven Press, New York.
38. Si-Hoe S.-L., de Bree F.M., Nijenhuis M., Davies J.E., Howell L.M.C., Tinley H., Waller S.J., Zeng Q., Zalm R., Sonnemans M., Van Leeuwen F.W., Burbach J.P.H., Murphy D. Endoplasmic reticulum derangement in hypothalamic neurons of rats expressing a familial neurohypophysial diabetes insipidus mutant vasopressin transgene. FASEB J. 14:2000;1680-1684.
39. Si-Hoe S.-L., Carter D.A., Murphy D. Physiological regulation of vasopressin mRNA abundance and poly(A) tail length: tissue and species differences revealed by comparative analysis in transgenic rodents. Physiol. Genomics. 5:2001;1-9.
40. Swanson L.W., Sawchenko P.E. Hypothalamic integration: organization of the paraventricular and supraoptic nuclei. Ann. Rev. Neurosci. 6:1983;269-324.
41. Szeto D.P., Ryan A.K., O'Connell S.M., Rosenfeld M.G. P-OTX: a PIT-1-interacting homeodomain factor expressed during anterior pituitary gland development. Proc. Natl. Acad. Sci. USA. 93:1996;7706-7710.
42. Vandesande F., Dierickx K., De Mey J. The origin of the vasopressinergic and oxytocinergic fibres of the external region of the median eminence of the rat hypophysis. Cell Tissue Res. 180:1977;443-452.
43. Waller, S.J., Murphy, D., 1995. Expression of rat vasopressin transgenes in rats. In: Saito, T., Kurokawa, K., Yoshida, S. (Eds.), The First Joint World Congress of Neurohypophysis and Vasopressin. Excerpta Medica International Congress Series 1098. Elsevier, Amterdam, pp. 89-98.
44. Waller S., Fairhall K.M., Xu J., Robinson I.C.A.F., Murphy D. Neurohypophysial and fluid homeostasis in transgenic rats expressing a tagged rat vasopressin prepropeptide in hypothalamic neurons. Endocrinology. 137:1996;5068-5077.
45. Waragai M., Lammers C.H., Takeuchi S., Imafuku I., Udagawa Y., Kanazawa I., Kawabata M., Mouradian M.M., Okazawa H. PQBP-1, a novel polyglutamine tract-binding protein, inhibits transcription activation by Brn2 and affects cell survival. Hum. Mol. Genet. 8:1999;977-987.
46. Wegner M., Drolet D.W., Rosenfeld M.G. POU-domain proteins: structure and function of developmental regulators. Curr. Opin. Cell Biol. 5:1993;488-498.
47. Wray S., Gainer H. Models for the study of cell-specific neuropeptide gene expression. Prog. Brain Res. 92:1992;59-76.
48. Xiao J.H., Davidson I., Metthes H., Garnier J.M., Chambon P. Cloning, expression, and transcriptional properties of the human enhancer factor TEF-1. Cell. 65:1991;551-568.
49. Zeng Q., Carter D.A., Murphy D. Cell specific expression of a vasopressin transgene in rats. J. Neuroendocrinol. 6:1994;469-477.